Did HHS chief Alex Azar work with ex-employer Lilly on drug rebate plans? A watchdog wants to know

The Trump administration in general—and HHS Secretary Alex Azar in particular—say a proposed crackdown on drug rebates is all about cutting costs for patients. But a nonprofit group wonders if the proposal has more to do with Azar's ties to the pharma industry, and it's asking the agency's watchdogs to investigate.